{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:21:43Z","timestamp":1787026903088,"version":"build-2736575974"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Alpha-synuclein (\u03b1-Syn) aggregation, transmission, and contribution to neurotoxicity represent central mechanisms underlying Parkinson\u2019s disease. The plant alkaloid \u201cnicotine\u201d was reported to attenuate \u03b1-Syn aggregation in different models, but its precise mode of action remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we investigated the effect of 2-week chronic nicotine treatment on \u03b1-Syn aggregation, neuroinflammation, neurodegeneration, and motor deficits in D-line \u03b1-Syn transgenic mice. We also established a novel humanized neuronal model of \u03b1-Syn aggregation and toxicity based on treatment of dopaminergic neurons derived from human induced pluripotent stem cells (iPSC) with \u03b1-Syn preformed fibrils (PFF) and applied this model to investigate the effects of nicotine and other compounds and their modes of action.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and discussion<\/jats:title>\n                    <jats:p>\n                      Overall, our results showed that nicotine attenuated \u03b1-Syn-provoked neuropathology in both models. Moreover, when investigating the role of nicotinic acetylcholine receptor (nAChR) signaling in nicotine\u2019s neuroprotective effects in iPSC-derived dopaminergic neurons, we observed that while \u03b14-specific antagonists reduced the nicotine-induced calcium response, \u03b14 agonists (e.g., AZD1446 and anatabine) mediated similar neuroprotective responses against \u03b1-Syn PFF-provoked neurodegeneration. Our results show that nicotine attenuates \u03b1-Syn-provoked neuropathology\n                      <jats:italic>in vivo<\/jats:italic>\n                      and in a humanized neuronal model of synucleinopathy and that activation of \u03b14\u03b22 nicotinic receptors might mediate these neuroprotective effects.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnins.2023.1239009","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T09:38:07Z","timestamp":1693474687000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Nicotine-mediated effects in neuronal and mouse models of synucleinopathy"],"prefix":"10.3389","volume":"17","author":[{"given":"Mohamed Bilal","family":"Fares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Alijevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Johne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassia","family":"Overk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Kondylis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Adame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Dulize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Peric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Nury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Battey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Guedj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Sierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Mc Hugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Rockenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyoun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Rissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hoeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel C.","family":"Peitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer","family":"Masliah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Mathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3892\/mmr.2021.12037","article-title":"Molecular insights into the benefits of nicotine on memory and cognition (Review)","volume":"23","author":"Alhowail","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"112187","DOI":"10.1016\/j.phytochem.2019.112187","article-title":"An electrophysiological characterization of naturally occurring tobacco alkaloids and their action on human alpha4beta2 and alpha7 nicotinic acetylcholine receptors","volume":"170","author":"Alijevic","year":"2020","journal-title":"Phytochemistry"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2202-14-6","article-title":"Time course and progression of wild type alpha-synuclein accumulation in a transgenic mouse model","volume":"14","author":"Amschl","year":"2013","journal-title":"BMC Neurosci."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular \u03b1-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J. Neurosci."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-540-69248-5_2","article-title":"Nicotine chemistry, metabolism, kinetics and biomarkers","volume":"192","author":"Benowitz","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1242\/bio.022111","article-title":"Systematic evaluation of markers used for the identification of human induced pluripotent stem cells","volume":"6","author":"Bharathan","year":"2017","journal-title":"Biol. Open"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2019.04.017","article-title":"Nicotine prevents alpha-synuclein accumulation in mouse and human iPSC-derived dopaminergic neurons through activation of the dopamine D3- acetylcholine nicotinic receptor heteromer","volume":"129","author":"Bono","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref8","article-title":"BBMap Suite","author":"Bushnell","year":"2018"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/bf02245195","article-title":"The short-term effect of nicotine chewing gum in patients with Parkinson's disease","volume":"117","author":"Clemens","year":"1995","journal-title":"Psychopharmacology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/s0006-8993(00)03087-0","article-title":"Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra","volume":"888","author":"Costa","year":"2001","journal-title":"Brain Res."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"6332","DOI":"10.1073\/pnas.0509313103","article-title":"Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin","volume":"103","author":"Dasgupta","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","article-title":"A framework for variation discovery and genotyping using next-generation DNA sequencing data","volume":"43","author":"DePristo","year":"2011","journal-title":"Nat. Genet."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"13010","DOI":"10.1073\/pnas.0903691106","article-title":"Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein","volume":"106","author":"Desplats","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/bf02244882","article-title":"Nicotine may relieve symptoms of Parkinson's disease","volume":"116","author":"Fagerstrom","year":"1994","journal-title":"Psychopharmacology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41583-020-00416-6","article-title":"Reverse engineering Lewy bodies: how far have we come and how far can we go?","volume":"22","author":"Fares","year":"2021","journal-title":"Nat. Rev. Neurosci."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"E912","DOI":"10.1073\/pnas.1512876113","article-title":"Induction of de novo alpha-synuclein fibrillization in a neuronal model for Parkinson's disease","volume":"113","author":"Fares","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.stem.2010.03.001","article-title":"Efficient derivation of functional floor plate tissue from human embryonic stem cells","volume":"6","author":"Fasano","year":"2010","journal-title":"Cell Stem Cell"},{"key":"ref19","author":"Garrison","year":"2012"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1177\/1087057112457821","article-title":"Characterizing human ion channels in induced pluripotent stem cell-derived neurons","volume":"17","author":"Haythornthwaite","year":"2012","journal-title":"J. Biomol. Screen."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1017\/S1461145710001665","article-title":"Acute nicotine enhances strategy-based semantic processing in Parkinson's disease","volume":"14","author":"Holmes","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.bbapap.2008.09.026","article-title":"Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation?","volume":"1794","author":"Hong","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.neuropharm.2010.12.032","article-title":"Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats","volume":"60","author":"Huang","year":"2011","journal-title":"Neuropharmacology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7150\/ijbs.23247","article-title":"Role of plant derived alkaloids and their mechanism in neurodegenerative disorders","volume":"14","author":"Hussain","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1523\/JNEUROSCI.19-03-01006.1999","article-title":"Characterization of G-protein-gated K+ channels composed of Kir3.2 subunits in dopaminergic neurons of the substantia nigra","volume":"19","author":"Inanobe","year":"1999","journal-title":"J. Neurosci."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/MNM.0b013e32832cc204","article-title":"Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study","volume":"30","author":"Itti","year":"2009","journal-title":"Nucl. Med. Commun."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.bbadis.2017.02.002","article-title":"Nicotine slows down oligomerisation of alpha-synuclein and ameliorates cytotoxicity in a yeast model of Parkinson's disease","volume":"1863","author":"Kardani","year":"2017","journal-title":"Biochim. Biophys. Acta"},{"key":"ref28","first-page":"274","article-title":"The effects of nicotine on Parkinson's disease","volume":"43","author":"Kelton","year":"2000","journal-title":"Brain Cogn."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13024-018-0276-2","article-title":"Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating alpha-synuclein transmission and neuroinflammation","volume":"13","author":"Kim","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e325","DOI":"10.1371\/journal.pbio.0050325","article-title":"The foxa2 gene controls the birth and spontaneous degeneration of dopamine neurons in old age","volume":"5","author":"Kittappa","year":"2007","journal-title":"PLoS Biol."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e1811","DOI":"10.1038\/cddis.2015.169","article-title":"Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons","volume":"6","author":"Koch","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature10648","article-title":"Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease","volume":"480","author":"Kriks","year":"2011","journal-title":"Nature"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"9262","DOI":"10.1074\/jbc.M109.081125","article-title":"Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies","volume":"285","author":"Lee","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0278-5846(03)00172-6","article-title":"Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease","volume":"28","author":"Lemay","year":"2004","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref35","author":"Li","year":"2013"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"8299","DOI":"10.1073\/pnas.1014041108","article-title":"Rapid induction and long-term self-renewal of primitive neural precursors from human embryonic stem cells by small molecule inhibitors","volume":"108","author":"Li","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/bpa.12371","article-title":"Neuroinflammation in synucleinopathies","volume":"26","author":"Lim","year":"2016","journal-title":"Brain Pathol."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4161\/auto.8.1.18313","article-title":"Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy","volume":"8","author":"Lu","year":"2012","journal-title":"Autophagy"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1073\/pnas.1913904117","article-title":"The process of Lewy body formation, rather than simply alpha-synuclein fibrillization, is one of the major drivers of neurodegeneration","volume":"117","author":"Mahul-Mellier","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jalz.2019.02.002","article-title":"Effects of single and combined immunotherapy approach targeting amyloid beta protein and alpha-synuclein in a dementia with Lewy bodies-like model","volume":"15","author":"Mandler","year":"2019","journal-title":"Alzheimers Dement."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS One"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","article-title":"Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders","volume":"287","author":"Masliah","year":"2000","journal-title":"Science"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1006\/exnr.2002.7900","article-title":"Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats","volume":"175","author":"Meshul","year":"2002","journal-title":"Exp. Neurol."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/978-3-211-45295-0_28","article-title":"Nicotine induces brain CYP enzymes: relevance to Parkinson's disease","volume":"70","author":"Miksys","year":"2006","journal-title":"J. Neural Transm. Suppl."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13073-015-0195-6","article-title":"CSN and CAVA: variant annotation tools for rapid, robust next-generation sequencing analysis in the clinical setting","volume":"7","author":"Munz","year":"2015","journal-title":"Genome Med."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/ntr\/nty189","article-title":"Therapeutic applications of nicotinic stimulation: successes, failures, and future prospects","volume":"21","author":"Newhouse","year":"2019","journal-title":"Nicotine Tob. Res."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.4049\/jimmunol.0902212","article-title":"Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses","volume":"183","author":"Nizri","year":"2009","journal-title":"J. Immunol."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s12576-016-0460-5","article-title":"Nicotine inhibits activation of microglial proton currents via interactions with alpha7 acetylcholine receptors","volume":"67","author":"Noda","year":"2017","journal-title":"J. Physiol. Sci."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.expneurol.2007.03.002","article-title":"Anti-fibrillogenic and fibril-destabilizing activity of nicotine in vitro: implications for the prevention and therapeutics of Lewy body diseases","volume":"205","author":"Ono","year":"2007","journal-title":"Exp. Neurol."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1242\/dev.02879","article-title":"Differences in neurogenic potential in floor plate cells along an anteroposterior location: midbrain dopaminergic neurons originate from mesencephalic floor plate cells","volume":"134","author":"Ono","year":"2007","journal-title":"Development"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1523\/JNEUROSCI.3784-11.2012","article-title":"Mimicking phosphorylation at serine 87 inhibits the aggregation of human alpha-synuclein and protects against its toxicity in a rat model of Parkinson's disease","volume":"32","author":"Oueslati","year":"2012","journal-title":"J. Neurosci."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.nbd.2009.06.004","article-title":"Brainstem Alzheimer's-like pathology in the triple transgenic mouse model of Alzheimer's disease","volume":"35","author":"Overk","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/s0006-8993(03)03195-0","article-title":"Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin","volume":"984","author":"Parain","year":"2003","journal-title":"Brain Res."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ejphar.2012.11.017","article-title":"Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation","volume":"698","author":"Paris","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1460-9568.2007.05636.x","article-title":"Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action","volume":"26","author":"Park","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1124\/mol.110.067561","article-title":"alpha6ss2* and alpha4ss2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease","volume":"78","author":"Perez","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"ref58","first-page":"1","article-title":"Focus on alpha4beta2* and alpha6beta2* nAChRs for Parkinson's disease therapeutics","volume":"3","author":"Perez","year":"2011","journal-title":"Mol. Cell. Pharmacol."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3233\/JPD-171248","article-title":"Best practices for generating and using alpha-synuclein pre-formed fibrils to model Parkinson's disease in rodents","volume":"8","author":"Polinski","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.bcp.2013.06.027","article-title":"Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice","volume":"86","author":"Quik","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/s0014-2999(99)00888-2","article-title":"Nicotinic receptors and Parkinson's disease","volume":"393","author":"Quik","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/mds.21900","article-title":"Nicotine and Parkinson's disease: implications for therapy","volume":"23","author":"Quik","year":"2008","journal-title":"Mov. Disord."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1111\/j.1471-4159.2006.04078.x","article-title":"Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates","volume":"98","author":"Quik","year":"2006","journal-title":"J. Neurochem."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1124\/pr.110.003269","article-title":"alpha6beta2* and alpha4beta2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease","volume":"63","author":"Quik","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/archneur.64.7.990","article-title":"Pooled analysis of tobacco use and risk of Parkinson disease","volume":"64","author":"Ritz","year":"2007","journal-title":"Arch. Neurol."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.neuro.2008.02.001","article-title":"Cigarette smoke, nicotine and cotinine protect against 6-hydroxydopamine-induced toxicity in SH-SY5Y cells","volume":"29","author":"Riveles","year":"2008","journal-title":"Neurotoxicology"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/sj.bjp.0703989","article-title":"Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice","volume":"132","author":"Ryan","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1523\/JNEUROSCI.2126-15.2016","article-title":"Smoking-relevant nicotine concentration attenuates the unfolded protein response in dopaminergic neurons","volume":"36","author":"Srinivasan","year":"2016","journal-title":"J. Neurosci."},{"key":"ref71","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1085\/jgp.201010532","article-title":"Nicotine up-regulates alpha4beta2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning","volume":"137","author":"Srinivasan","year":"2011","journal-title":"J. Gen. Physiol."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1124\/mol.112.077792","article-title":"Pharmacological chaperoning of nicotinic acetylcholine receptors reduces the endoplasmic reticulum stress response","volume":"81","author":"Srinivasan","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.nbd.2018.05.018","article-title":"Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type alpha-synuclein","volume":"117","author":"Subramaniam","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"9338","DOI":"10.1523\/JNEUROSCI.0877-14.2014","article-title":"Mitochondrial dysfunction induces Sarm1-dependent cell death in sensory neurons","volume":"34","author":"Summers","year":"2014","journal-title":"J. Neurosci."},{"key":"ref75","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.expneurol.2012.01.008","article-title":"Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of \u03b1-synucleinopathy","volume":"234","author":"Ubhi","year":"2012","journal-title":"Exp. Neurol."},{"key":"ref76","doi-asserted-by":"publisher","first-page":"6236","DOI":"10.1523\/JNEUROSCI.0567-10.2010","article-title":"Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors","volume":"30","author":"Ubhi","year":"2010","journal-title":"J. Neurosci."},{"key":"ref77","volume-title":"Nicotine and other tobacco compounds in neurodegenerative and psychiatric diseases \u2013 overview of epidemiological data on smoking and preclinical and clinical data on nicotine","author":"Veljkovic","year":"2018"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"e0128224","DOI":"10.1371\/journal.pone.0128224","article-title":"Chronic Anatabine treatment reduces Alzheimer's disease (AD)-like pathology and improves socio-behavioral deficits in a transgenic mouse model of AD","volume":"10","author":"Verma","year":"2015","journal-title":"PLoS One"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1212\/wnl.57.6.1032","article-title":"Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study","volume":"57","author":"Vieregge","year":"2001","journal-title":"Neurology"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/j.1468-1331.2007.01949.x","article-title":"Chronic high dose transdermal nicotine in Parkinson's disease: an open trial","volume":"14","author":"Villafane","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"ref81","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/jnc.13249","article-title":"Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies","volume":"139","author":"Villar-Pique","year":"2016","journal-title":"J. Neurochem."},{"key":"ref82","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.neuropharm.2006.04.015","article-title":"Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle","volume":"51","author":"Visanji","year":"2006","journal-title":"Neuropharmacology"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","article-title":"Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death","volume":"72","author":"Volpicelli-Daley","year":"2011","journal-title":"Neuron"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40478-019-0696-4","article-title":"Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration","volume":"7","author":"Wang","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"ref85","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1002\/stem.1152","article-title":"Specification of midbrain dopamine neurons from primate pluripotent stem cells","volume":"30","author":"Xi","year":"2012","journal-title":"Stem Cells"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s10072-014-1652-5","article-title":"Effect of nicotine on L-dopa-induced dyskinesia in animal models of Parkinson's disease: a systematic review and meta-analysis","volume":"35","author":"Xie","year":"2014","journal-title":"Neurol. Sci."},{"key":"ref87","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/mds.25817","article-title":"ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease","volume":"29","author":"Zhang","year":"2014","journal-title":"Mov. Disord."}],"updated-by":[{"DOI":"10.3389\/fnins.2025.1662162","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000}}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2023.1239009\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T13:33:42Z","timestamp":1754055222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2023.1239009\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":85,"alternative-id":["10.3389\/fnins.2023.1239009"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2023.1239009","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]},"article-number":"1239009"}}